Asked by: Tonia Antoniazzi (Labour - Gower)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential impact of increased rates of breastfeeding on cost savings for the NHS.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The public health benefits of breastfeeding for child and maternal health are significant and well established. Research published in the British Medical Journal suggests that increasing breastfeeding rates, both in terms of duration and exclusivity, is likely to generate substantial cost savings to the National Health Service, although the actual amounts saved will depend on the extent of this increase.
Through the Family Hubs and Start for Life Programme, we are investing £50 million to increase the range of specialist support, which is enabling more parents to access face-to-face and virtual support whenever they need it. One of the objectives of the programme is to improve the evidence base around the impact of breastfeeding interventions, and the specific combination of interventions that are effective in different circumstances. This is expected to strengthen the case for further, more widespread investment in the future.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment has she made of the potential merits of a men's health strategy for the economy.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Whilst no specific assessment has been made, we are already taking action to address the health issues that disproportionately impact men. This includes through policies announced on International Men’s Day, such as the appointment of a Men’s Health Ambassador, to raise the profile of men’s health issues. The Major Conditions Strategy will also focus on improving health outcomes linked to major condition areas like cancer, cardiovascular, and chronic respiratory diseases that disproportionately impact men.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she has made a recent assessment of the potential merits of creating a national naloxone programme.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what her planned timetable is for publishing a response to her Department's consultation on Expanding access to naloxone.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the availability of naloxone across England.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Naloxone is highly effective in reducing opioid overdose-related deaths, and the Government is working to widen access to, and increase the uptake of, this life saving drug. A prescription only medicine that is available across the United Kingdom, naloxone can be prescribed by a doctor or non-medical prescriber or provided, under a Patient Group Direction. It can also be supplied without prescription by drug services, which include specialist National Health Service and voluntary sector treatment services, as well as community pharmacies providing other substance misuse services across the UK.
Naloxone has been available for anyone to use in an emergency since 2005. There is good awareness of it, supported by earlier guidance by the Department and its agencies in 2015, 2018, 2019, and 2023. Drug treatment services and their suppliers also provide independent awareness-raising materials, targeting people who use opioids.
The Government launched a UK-wide public consultation to seek views on our proposal to amend the Human Medicines Regulations 2012 so that more professionals, services, and family members can give out take-home naloxone supplies. The consultation closed on 6 March 2024, and the responses are currently being analysed. The Government will publish its official response shortly.
The Government is working to increase naloxone carriage, and has provided additional investment in drug treatment services to support this work. In England, local authorities and their partners have been increasing naloxone supply in recent years. There are now three naloxone products available, and supply has been meeting demand. To enable the Government to respond to any future change in demand for naloxone, the Department is working with the Home Office to model scenarios where demand for naloxone may increase, and has conducted a commercial engagement exercise to better understand the naloxone market, and the market’s capacity to respond to changes in demand.
Asked by: Helen Grant (Conservative - Maidstone and The Weald)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent progress she has made on retaining more GPs.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
There were 2,799 more full time equivalent (FTE) doctors working in general practice (GP) in December 2023, compared to December 2019. The Government is working with NHS England to increase the GP workforce in England. This includes measures to boost recruitment, address the reasons why doctors leave the profession, and encourage them to return to practice. NHS England has made available a number of retention schemes, to boost the GP workforce.
Asked by: Ellie Reeves (Labour - Lewisham West and Penge)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that NHS integrated care boards commission (a) end-of-life and (b) other palliative care for people in all age groups.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
While the National Health Service has always been required to commission appropriate palliative and end of life care services to meet the reasonable needs of their population, in 2022, palliative care services were added to the list of services an integrated care board (ICB) must commission, promoting a more consistent national approach and supporting commissioners in prioritising palliative and end of life care in all settings. To support ICBs in this duty, NHS England has published statutory guidance and service specifications for both adults and children.
From April 2024, NHS England will include palliative and end of life care in the list of topics for its regular performance discussions between national and regional leads. Additionally, NHS England has commissioned the development of a palliative and end of life care dashboard, which brings together relevant, all age local data in one place. The dashboard helps commissioners understand the palliative and end of life care needs of both adults and children in their local population, enabling ICBs to put plans in place to address and track the improvement of health inequalities.
NHS England has also funded seven Palliative and End of Life Care Strategic Clinical Networks, each with a dedicated Children and Young People Lead. These networks support commissioners in the delivery of outstanding clinical and personalised care for people in the last year of life and reduce local variation.
Asked by: Karin Smyth (Labour - Bristol South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential impact of capacity in district nursing on the timeliness of patient discharge from hospital in 2023.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
Between the end of March 2023 and the end of March 2024, the number of supported discharges for patients assessed as no longer meeting the criteria to reside has increased by 17% for patients on pathway 1. Pathway one is for patients returning to their usual place of residence with new or additional health or social care needs. Packages of post-discharge support for these patients may include support from district nurses.
We recognise the importance of increasing district nursing capacity. Through the NHS Long Term Workforce Plan we aim to increase training places for district nurses by 150% by 2031/32. As of January 2024, there were 4,295 full-time equivalent district nurses working in community services in NHS trusts and other core organisations in England, this is 0.5% fewer than in 2019.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to encourage pregnant women to undertake smoking cessation programmes.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
Smoking is the number one entirely preventable cause of ill-health, disability, and death in this country. It is responsible for 80,000 yearly deaths in the United Kingdom, and one in four of all UK cancer deaths. Smoking in pregnancy increases the risk of stillbirth, miscarriage, and sudden infant death.
As set out in Stopping the Start: our new plan to create a smokefree generation, we are establishing a financially incentivised scheme to help pregnant smokers and their partners to quit smoking, with smoking cessation support. This evidence-based intervention will encourage pregnant women to give up smoking, and remain smokefree throughout pregnancy and beyond, helping to improve the health and wellbeing of both mother and baby.
The objective is to have all maternity trusts that wish to participate in the scheme signed up by the end of 2024, so that all pregnant women who smoke in participating areas will be offered the opportunity to join the incentive scheme by December 2024.
This financial incentive scheme builds upon the NHS Long Term Plan’s ambition to ensure that all pregnant smokers can access behavioural support to quit from within maternity services, as well as additional funding for mass marketing campaigns on stopping smoking.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will develop a (a) rehabilitation strategy and (b) single accountable lead in every NHS Trust and Integrated Care Board area.
Answered by Helen Whately - Minister of State (Department of Health and Social Care)
National Health Service bodies and local authorities should ensure local recovery, rehabilitation, and reablement services are commissioned effectively and sustainably, and meet the needs of their local population. This may be provided as part of intermediate care services, and should be done in collaboration with relevant organisations, including the voluntary and community sector, and care providers.
NHS England has published the Intermediate care framework for rehabilitation, reablement and recovery following hospital discharge, which recommends systems identify an Allied Health Professional lead to progress implementation of the new model, both within the hospital and in the community.
Integrated care boards have flexibility over the arrangements of their own governance, including board membership, and are able to go beyond the statutory minimums to appoint more local authority, NHS provider, or primary care representatives to board membership, in order to tackle local priority issues.